**4- SARS-CoV-2 et phénomènes de facilitation de l’infection par les anticorps (ADE)**

**Lire aussi :**

* <https://pubmed.ncbi.nlm.nih.gov/33485405/>
* <https://pubmed.ncbi.nlm.nih.gov/32908214/>
* <https://pubmed.ncbi.nlm.nih.gov/34384810/>
* <https://pubmed.ncbi.nlm.nih.gov/32506725/>
* <https://pubmed.ncbi.nlm.nih.gov/32845733/>
* <https://www.biorxiv.org/content/10.1101/2021.08.22.457114v1>
* <https://pubmed.ncbi.nlm.nih.gov/33717193/>
* <https://www.researchsquare.com/article/rs-1054360/v1>
* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512237/pdf/10.1177_20587384211050199.pdf>
* <https://www.nature.com/articles/s41564-020-00789-5#Sec7>
* <https://pubmed.ncbi.nlm.nih.gov/34579572/>
* <https://journals.sagepub.com/doi/full/10.1177/20587384211050199>